Clinical Trials Logo

Filter by:
NCT ID: NCT02469168 Terminated - Wounds and Injury Clinical Trials

Epidermal Coverage of Traumatic Wound Injuries Via Use of Autologous Spray Skin Applied Over Bilayered Wound Matrix

Start date: December 2014
Phase: N/A
Study type: Interventional

The purpose of this investigation is to evaluate the safety, tolerability, preliminary and long-term effectiveness of utilizing the ReCell Autologous Cell Harvesting Device (ReCell) combined with widened split-thickness skin graft (STSG) mesh onto the dermal regenerate INTEGRA™ Meshed Bilayer Wound Matrix (MBWM) for healing of full-thickness wounds.

NCT ID: NCT02469116 Terminated - Ovarian Cancer Clinical Trials

Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma

Start date: January 2006
Phase: Phase 2
Study type: Interventional

In this study the investigators will be using an AUC of 6 based on creatinine clearance using the Carboplatin dosing formula used for Gynecologic Oncology Group protocols. Given that myelosuppression was significant using the docetaxel dose of 75 mg/m*2 in the SCOTROC trial, the prophylactic use of pegylated G-CSF in this Phase II trial is warranted. The expectation would be that patients will be able to receive their cycles in a more timely fashion, with less delays, thereby allowing for improved outcomes and decreased hospitalizations due to myelosuppression.

NCT ID: NCT02468778 Terminated - Clinical trials for Coronary Artery Disease

SHIELD II Clinical Investigation

SHIELD II
Start date: August 2015
Phase: N/A
Study type: Interventional

The HeartMate PHP System is a temporary (<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is the appropriate therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events.

NCT ID: NCT02468661 Terminated - Clinical trials for Non-Small Cell Lung Cancer

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Start date: September 23, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study was to determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of INC280 in combination with erlotinib in the Phase Ib of this study, and to assess the anti-tumor activity and safety of INC280 alone, and in combination with erlotinib, versus platinum with pemetrexed in the Phase II of this study, in adult patients with EGFR mutated, cMET amplified, advanced/metastatic non-small cell lung cancer with acquired resistance to prior EGFR TKI.

NCT ID: NCT02468583 Terminated - Clinical trials for Post-traumatic Osteoarthritis of the Knee

Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee

Start date: February 2015
Phase: Phase 2
Study type: Interventional

This study was a double-blind, randomized, parallel group, proof of concept study comparing FX006 to Kenalog®-40 (triamcinolone acetonide injectable suspension, USP) in patients with post-traumatic osteoarthritis of the knee.

NCT ID: NCT02468557 Terminated - Clinical trials for Relapsed/Refractory Pancreatic Ductal Adenocarcinoma

Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma

Start date: July 30, 2015
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the safety of single agent idelalisib and to evaluate safety and define the maximum tolerated dose (MTD) of idelalisib in combination with chemotherapy in adults with metastatic pancreatic ductal adenocarcinoma.

NCT ID: NCT02468414 Terminated - Clinical trials for Anemia of End Stage Renal Disease

TARGTEPO Treatment for Anemia in PD US Trial

Start date: June 2015
Phase: Phase 2
Study type: Interventional

The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment in Peritoneal Dialysis patients

NCT ID: NCT02467634 Terminated - Clinical trials for Age-Related Macular Degeneration

Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD

RADIANT
Start date: June 2015
Phase: Phase 2
Study type: Interventional

A fellow eye controlled study of HUCNS-SC sub-retinal transplantation in subjects with bilateral GA AMD. All subjects will be assigned to HUCNS-SC transplantation.

NCT ID: NCT02467075 Terminated - Acute Kidney Injury Clinical Trials

Double-Blind Placebo-Controlled CIN Trial

Start date: July 2015
Phase: Phase 4
Study type: Interventional

This double-blinded placebo-controlled non-inferiority study will examine the incidence and significance of contrast-induced acute kidney injury following intravenous iodinated contrast material administration in subjects with stage IIIB or stage IV chronic kidney disease. Subjects will be scheduled for clinically indicated CT of the abdomen and/or pelvis to evaluate for suspected intra-abdominal infection. Subjects will be randomized to receive either weight-based low-osmolality iodinated contrast material or saline. The primary outcome measure will be the incidence of stage II AKI by AKIN criteria.

NCT ID: NCT02466763 Terminated - Deafness Clinical Trials

Prospective Study of Round Window Versus Cochleostomy Approach to CI Surgery

Start date: May 2015
Phase: N/A
Study type: Interventional

To the investigators' knowledge, no clinical study has prospectively investigated the relationship between surgical insertion technique, intracochlear electrode location, and postoperative hearing outcomes. To this end, the investigators are conducting a multicenter prospective randomized controlled double-blinded study comparing round window and cochleostomy cochlear implant electrode insertion.